Marrow Transplantation from Donors Other Than HLA Genotypically Identical Siblings: The Immunogenetics of Acute Graft Versus Host Disease
Bone marrow transplantation has become an accepted form of treatment for several hematologic malignancies . However, only 40% of patients who are otherwise eligible for transplantation will have an HLA genotypically identical sibling. In 1975, the Seattle Marrow Transplant Team began using related donors other than HLA genotypically identical siblings in hopes of expanding the acceptable limits of disparity and thereby increasing the chance of a patient having an acceptable donor. This study analyzes how immunogenetic differences between patient and donor have an impact upon the incidence and day of onset of acute graft-versus-host disease (AGVHD), a major complication of marrow transplantation.